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Abstract Nonlinear mixed-effects models are frequently
used for pharmacokinetic data analysis, and they ac-
count for inter-subject variability in pharmacokinetic
parameters by incorporating subject-specific random
effects into the model. The random effects are often
assumed to follow a (multivariate) normal distribution.
However, many articles have shown that misspecifying
the random-effects distribution can introduce bias in
the estimates of parameters and affect inferences about
the random effects themselves, such as estimation of the
inter-subject variability. Because random effects are un-
observable latent variables, it is difficult to assess their
distribution. In a recent paper we developed a diag-
nostic tool based on the so-called gradient function to
assess the random-effects distribution in mixed models.
There we evaluated the gradient function for general-
ized liner mixed models only and in the presence of a
single random effect. However, assessing the random-
effects distribution in nonlinear mixed-effects models is
more challenging, especially when multiple random ef-
fects are present, and therefore the results from linear
and generalized linear mixed models may not be valid
for such nonlinear models. In this paper, we further
investigate the gradient function and evaluate its per-
formance for such nonlinear mixed-effects models which
are common in pharmacokinetics and pharmacodynam-
ics. We use simulations as well as real data from an
intensive pharmacokinetic study to illustrate the pro-
posed diagnostic test.
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Introduction
Nonlinear mixed-effects models are being widely used
in pharmacokinetics to study the pharmacological pro-
cesses within the body after administration of a drug in
order to characterize drug disposition (absorption, dis-
tribution, metabolism, and excretion). The term “Mixed-
effects” refers to the presence of both fixed effects and
random effects in the model. Fixed effects are regres-
sion parameters associated with covariates, while ran-
dom effects are subject-specific random quantities in-
corporated to capture the inter-subject variability.
In pharmacokinetics, it is important to understand
the inter-subject variation in pharmacokinetic param-
eters and its association with subject characteristics,
which could provide useful information, for example,
in developing dosing guidelines. Nonlinear mixed-effects
models account for the inter-subject variability by adding
subject-specific random effects to the model. The ran-
dom effects are latent and hence unobservable variables
that follow a distribution, which is unknown. Note that
the random effects also capture the potential correlation
between repeated measurements on the same subject,
which must not be ignored in the analysis.
To fit a nonlinear mixed-effects model, one often
needs to assume a distribution for the random effects.
Inferences are then based on the marginal likelihood
function after integrating out the random effects over
their assumed distribution. It is common to assume that
the random effects follow a (multivariate) normal dis-
tribution. The normality assumption makes computa-
2 Reza Drikvandi
tion of the marginal likelihood more feasible. However,
it is well understood that misspecifying the random-
effects distribution can introduce bias in the estimates
of fixed-effects parameters (see, for example, [11,1,16,
2,9]) and it also affects the operating characteristics of
hypothesis tests (see, for example, [10,15]). More im-
portantly, inferences about the random effects them-
selves, such as estimation of the inter-subject variabil-
ity, are more likely to be affected by misspecification of
the random-effects distribution. For instance, the nor-
mality assumption often forces the predictions of ran-
dom effects to reflect normality, even when the cor-
rect random-effects distribution is far from normal [23].
Therefore, to obtain reliable inference it is important
to check the appropriateness of the assumed random-
effects distribution.
In the literature, a number of diagnostic tools have
been suggested for assessing the random-effects distri-
bution in linear mixed models [14,13,5] and also in gen-
eralized linear mixed models [20,18,25,22,3,12]. How-
ever, to the best of our knowledge, there is only one di-
agnostic tool available for checking the random-effects
distribution in nonlinear mixed-effects models. We de-
veloped this diagnostic test recently [8], which is based
on the so-called gradient function introduced in [24].
In our paper [8] we showed, via simulations, that the
diagnostic test based on the gradient function performs
well in detecting misspecification of the random-effects
distribution. However, the performance of this test was
evaluated in the case of generalized linear mixed mod-
els only and in the presence of a single random ef-
fect. It is not known how the diagnostic test performs
in nonlinear mixed-effects models, especially with mul-
tiple random effects, which are common in pharma-
cokinetics and pharmacodynamics. Obviously, nonlin-
ear mixed-effects models are more complex than linear
and generalized linear mixed models, and moreover, the
presence of multiple random effects makes assessment
of the random-effects distribution much more difficult.
Therefore, the results from linear and generalized lin-
ear mixed models may not be valid for such nonlinear
models. In this paper, we aim to investigate and evalu-
ate the performance of the diagnostic test based on the
gradient function in such nonlinear mixed-effects mod-
els. We use simulations and real data from an intensive
pharmacokinetic study.
Methods
Nonlinear mixed-effects models
In this subsection, we briefly explain the general form
of nonlinear mixed-effects models for pharmacokinetic
data analysis. Consider a pharmacokinetic study in which
N subjects are followed over time after administration
of a drug. Let Yi1, . . . , Yini be ni repeated measure-
ments on the ith subject, where Yij is the outcome for
subject i measured at time tij . For example, Yij could
be the blood sample drawn after administration of the
anti-asthmatic agent theophylline. Also, let Ui denote a
vector of covariates representing conditions under which
measurements on subject i are observed. For example,
when each subject receives a single oral dose, say di,
then Ui = di. Finally, assume that Ai is a vector of
characteristics of subject i that do not change during
the study. For example, Ai could include age, gender,
height, ethnicity, and smoking status. Now, the nonlin-
ear mixed-effects model can be expressed as a two-stage
hierarchy as follows: (See [7])
Stage 1: Individual-Level Model
Yij = m(tij , Ui, θi) + εij , j = 1, . . . , ni,
Stage 2: Population Model
θi = d(Ai, β, bi), i = 1, . . . , N.
(1)
In Stage 1, m is a “known” nonlinear function of time
which also depends on the subject conditions Ui and an
r × 1 vector of pharmacokinetic parameters θi, specific
to subject i. For example,m could be a one-compartment
model as in (5), where θi = (kai, kei, Cli)
′ and Ui = di.
Also, εij ’s are independent measurements errors, each
of which has a normal distribution with mean 0 and
variance σ2. In Stage 2, d is an r-dimensional function
that describes the relationship between the elements
of θi and between-subject covariates Ai in terms of a
p× 1 fixed parameter β whose elements are referred to
as fixed effects, and a q × 1 vector bi of random effects
representing the inter-subject variability. For instance,
d could be the three-dimensional function in (6). Note
that because the pharmacokinetic parameters can vary
from subject to subject, the random effects bi are in-
corporated into the model to capture the inter-subject
variability through a hierarchical analysis. The random
effects bi, which are unobservable variables with an un-
known distribution, are assumed to have a zero mean
and a covariance matrix D whose elements are known
as variance components.
Let γ = (β, σ2, D)′ represent all unknown param-
eters in model (1). The estimates of parameters can
then be obtained using the maximum likelihood esti-
mation method. The maximum likelihood approach re-
quires some assumption on the distribution of random
effects. For this, assume that the random effects bi fol-
low a specific distribution, which is denoted by G. A
typical choice for G is the multivariate normal distri-
bution, i.e., bi ∼ N(0, D). The log-normal distribution
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is also used in pharmacokinetics. Denoting the condi-
tional distribution of the outcome Yij given the random
effects bi by fi(yij |bi), one can write the marginal log-
likelihood function for model (1) as follows
l(γ) = ln
N∏
i=1
∫
Rq
[ ni∏
j=1
fi(yij |bi)
]
dG(bi). (2)
The integral in marginal log-likelihood (2) may not be
solved analytically, and it requires numerical approx-
imation. We use Gauss-Hermite quadrature (see, e.g.,
[19]), which can provide reliable approximations. The
integral approximation and the maximisation of the
log-likelihood function (2) with respect to γ can be
done simultaneously in a standard software package like
NONMEM, SAS or R. In this paper, we use PROC
NLMIXED in SAS to obtain the maximum likelihood
estimates of parameters.
Obviously, the random-effects distribution G is cru-
cial in the calculation of the log-likelihood function (2)
and, as discussed in the introduction, a misspecified
random-effects distribution can lead to biased parame-
ter estimates and invalid inferences. It is therefore im-
portant to check whether or not the assumed random-
effects distribution is correctly specified. It should be
pointed out that since random effects are unobservable
variables, assessing their distribution is difficult.
A diagnostic tool for the random-effects distribution
As discussed in the previous subsection, to obtain the
maximum likelihood estimates of parameters in the non-
linear mixed-effects model (1), one needs to assume a
distribution for the random effects bi. In this subsection,
we describe a diagnostic tool to verify whether or not
an assumed random-effects distribution G is correctly
specified.
Let Yi = (Yi1, . . . , Yini)
′ be the vector of repeated
measurements on subject i, i = 1, . . . , N . To check the
adequacy of an assumed random-effects distribution G,
[24] suggested to use the so-called gradient function
given by
∆ (G, b) =
1
N
N∑
i=1
fi (yi|b)
fi (yi|G) , b ∈ R
q, (3)
where fi(yi|b) and fi(yi|G) are, respectively, the condi-
tional (given random-effect point b) and marginal dis-
tributions of Yi. The gradient can be interpreted as an
average of likelihood ratios, each ratio measuring how
much more likely Yi is to be observed for subject i
if the corresponding random effect bi equals b rather
than being sampled from the distribution G. Note that
calculation of the gradient function is easy because it
only requires the calculation of the marginal and condi-
tional distributions of all N subjects. [24] showed that
if the random-effects distribution G is correctly spec-
ified, then ∆ (G, b) ≤ 1 for all b ∈ Rq, and moreover
∆ (G, b) = 1 for all b in the support of G. Hence, de-
viations of the gradient function from 1 in the support
points ofG indicate inadequacy ofG and that the model
can be improved by replacing G by some other random-
effects distribution. They suggested to plot the gradi-
ent function versus points b in the support of G, and
if the gradient plot is close to 1 then the adequacy of
G is confirmed. Despite the simplicity of this graphical
approach, it is not clear how misspecification can be
distinguished from random variability by such a plot,
especially when bi is not a scalar which requires eval-
uating a three or higher dimensional plot of gradient
function.
Based on the gradient function (3), we recently de-
veloped a formal diagnostic test for the random-effects
distribution (see [8]). Let the null hypothesis H0 says
the random-effects distribution G is correctly specified
and the alternative hypothesis Ha says otherwise. Hav-
ing considered all deviations of the gradient function
from 1, we constructed a test statistic for testing H0
versus Ha as follows
T =
∫
Rq
(
∆ˆ(Gˆ, b)− 1)2dGˆ(b), (4)
where Gˆ is the estimated random-effects distribution
obtained by replacing the covariance matrix D by its
maximum likelihood estimate, and ∆ˆ denotes the esti-
mated gradient function based on Gˆ obtained simply
by replacing the unknown parameters in fi (yi|b) and
fi(yi|Gˆ) by their maximum likelihood estimates. If T
deviates much from 0, one can reject H0 indicating that
the assumed random-effects distribution G is not ade-
quate for random effects. The test statistic (4) consid-
ers a weight for each deviation of the gradient function
from 1 for each random-effect point b. The weight is the
estimated probability mass in point b. Note that T can
be calculated using Monte Carlo integration.
The asymptotic distribution of T is given in Theo-
rem 1 of [8], which is actually the distribution of weighted
sum of independent chi-squared random variables each
with one degree of freedom. The weights are eigenvalues
of the square matrix A′QA (specified in Theorem 1 of
[8]), which can be calculated using a software package.
The asymptotic distribution of T should be used
when the sample size N is sufficiently large. For small-
sample situations, we propose a parametric bootstrap
procedure to obtain the finite-sample distribution of the
test statistic T in (4). The key step in our bootstrap
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procedure, in order to obtain a bootstrap sample, is to
first generate random effects bsi , i = 1, . . . , N , from Gˆ
and then generate a bootstrap sample Y si , i = 1, . . . , N ,
from fˆi(yi|bsi ). We use 200 bootstrap samples to con-
duct the bootstrap test. Below we illustrate how the
asymptotic and bootstrap tests based on (4) can be
performed.
Implementation of the asymptotic test
The asymptotic test can be carried out by the following
steps:
1. Generate K, say 1000, random-effect points bk from
Gˆ.
2. Compute the gradient function (3) and its squared
deviation from 1 for each bk.
3. Calculate the test statistic T being the average of
the K squared deviations obtained in step 2 (which
is a Monte Carlo approximation of T ).
4. If T is greater than the 95% quantile of the asymp-
totic distribution (mentioned above), then rejectH0,
indicating that the assumed random-effects distri-
bution G is not appropriate for random effects. Oth-
erwise, G is correctly specified.
Implementation of the bootstrap test
The bootstrap test can be carried out by the following
steps:
1. Generate K, say 1000, random-effect points bk from
Gˆ.
2. Compute the gradient function (3) and its squared
deviation from 1 for each bk.
3. Calculate the test statistic T being the average of
the K squared deviations obtained in step 2 (which
is a Monte Carlo approximation of T ), and denote
it by Tobs.
4. For each bootstrap step s, s = 1, . . . , 200, repeat the
following two steps:
i. First generate random effects bsi , i = 1, . . . , N ,
from Gˆ and then generate a bootstrap sample
Y si , i = 1, . . . , N , from fˆi(yi|bsi ).
ii. Calculate the test statistic T for the bootstrap
sample obtained in step i and denote it by T s.
5. If the proportion of T s exceeding Tobs is less than
0.05, then reject H0, indicating that the assumed
random-effects distribution G is not appropriate for
random effects. Otherwise, G is correctly specified.
The above steps for the asymptotic and bootstrap
tests can be coded in a standard software package. A
SAS code is available from the author upon request.
In [8] we showed, via simulations, that both the
asymptotic and bootstrap tests perform well in detect-
ing misspecification of the random-effects distribution
in the case of generalized linear mixed models with one
random effect. However, it is not known how the tests
perform in nonlinear mixed-effects models, especially
in the presence of multiple random effects, as in (1). In
those cases, as discussed in the introduction, assessing
the random-effects distribution is more challenging. In
the next section, we use simulations and real data to in-
vestigate the performance of both the asymptotic and
bootstrap tests for assessing the random-effects distri-
bution in the nonlinear mixed-effects model (1).
Results
Real data: theophylline data
Theophylline is a well-known anti-asthmatic agent, ad-
ministered orally [4,6,7]. In an intensive pharmacoki-
netic study, 12 subjects were given the same oral dose
(mg/kg) of theophylline, and blood samples were taken
at several times following administration were assayed
for theophylline concentration [7]. The individual pro-
files, presented in Figure 1, show that the theophylline
concentrations have a similar shape for all subjects, but
peak concentration achieved, rise, and decay vary sig-
nificantly across the subjects. These differences are due
to the inter-subject variation in the underlying phar-
macokinetic processes, understanding of which is crit-
ical for developing dosing guidelines. To characterize
these processes formally, we consider the following one-
compartment model with first-order absorption and elim-
ination: (see also [7])
Ci(tij) =
dikaikei
CLi(kai − kei)
[
exp(−keitij)−exp(−kaitij)
]
+εij ,
(5)
where Ci(tij) is the observed theophylline concentration
on subject i at time tij , di is the dose administered to
subject i, kai is the fractional absorption rate constant
for subject i, kei is the fractional elimination rate con-
stant for subject i, and CLi is the clearance for subject
i. Note that the one-compartment model (5) can equiv-
alently be written based on the volume of distribution
(V ) by using the relationship CL = ke.V (see [17] p.
354).
From Figure 1, the pharmacokinetic parameters vary
from subject to subject, therefore we include subject-
specific random effects in the pharmacokinetic param-
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Fig. 1 Theophylline data: individual profiles for 12 subjects.
eters as follows
CLi = exp(β1 + bi1),
kai = exp(β2 + bi2),
kei = exp(β3 + bi3),
(6)
in which the vector of random effects bi = (bi1, bi2, bi3)
′
is assumed to have mean 0 and covariance matrix D
given by
Cov(bi) = D =
d11 d12 d13d12 d22 d23
d13 d23 d33
 .
Assuming that bi follows a multivariate normal dis-
tribution, we obtained the maximum likelihood esti-
mates of parameters (fixed-effect parameters, residual
variance, and variance components of random effects)
in the one-compartment model (5-6) along with their
associated standard errors. The results are reported in
Table 1. Using the estimates of variance components
in this table, we computed the estimated correlation
matrix of bi as follows
Ĉorr(bi) =
 1.000 −0.098 0.672−0.098 1.000 −0.261
0.672 −0.261 1.000
 ,
which indicates that the clearance is highly correlated
with the fractional elimination (Corr(b1i, bi3) = 0.672)
while it has a very small correlation with the fractional
absorption (Corr(b1i, bi2) = −0.098). Hence, it might be
reasonable to assume the clearance and the fractional
elimination are described by the same random effect,
rather than two (highly) correlated ones. Considering
the relationship CL = ke.V , we might let bi3 = λbi1,
Table 1 Theophylline data: the maximum likelihood esti-
mates of parameters (fixed-effect parameters, residual vari-
ance, and variance components of random effects) in the
one-compartment model (5) with the random effects bi =
(bi1, bi2, bi3)′ given in (6), along with the associated stan-
dard errors.
Parameter Estimate (s.e.)
Fixed effects:
β1 −3.277 (0.046)
β2 0.537 (0.063)
β3 −2.454 (0.064)
Residual variance:
σ2 0.624 (0.083)
Variance components of bi:
d11 0.057 (0.022)
d12 −0.012 (0.018)
d22 0.264 (0.054)
d13 0.030 (0.020)
d23 −0.025 (0.017)
d33 0.035 (0.017)
−2 log-likelihood 341.7
where λ is a fixed variance inflation parameter to be
estimated. Then, (6) can be simplified as
CLi = exp(β1 + bi1),
kai = exp(β2 + bi2),
kei = exp(β3 + λbi1).
(7)
Now, we fit the one-compartment model (5) with
the two random effects bi1 and bi2 given in (7) to the
theophylline data. Again it is needed to assume a dis-
tribution for the random effects, and here a bivariate
normal distribution is a handy choice. The parameter
estimates under the bivariate normality assumption of
bi1 and bi2 are calculated and reported in Table 2. The
results suggest that (7) produces a better fit than (6)
in terms of log-likelihood.
To verify the appropriateness of the bivariate nor-
mal distribution for the random effects bi1 and bi2, we
would apply the diagnostic test (4). Since the perfor-
mance of this diagnostic test has not yet been examined
for nonlinear mixed-effects models and subsequently for
one-compartment models, we first conduct a simula-
tion study to see whether the diagnostic test (4) has a
good power in detecting misspecification of the random-
effects distribution in such nonlinear models.
Simulations
In this subsection, we conduct a simulation study in
accordance with the one-compartment model (5) used
for the theophylline data. For each sample size N =
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Table 2 Theophylline data: the maximum likelihood esti-
mates of parameters (fixed-effect parameters, residual vari-
ance, variance components of random effects, and variance
inflation parameter) in one-compartment model (5) with the
random effects bi = (bi1, bi2)′ specified in (7), along with the
associated standard errors.
Parameter Estimate (s.e.)
Fixed effects:
β1 −3.216 (0.081)
β2 0.464 (0.199)
β3 −2.439 (0.064)
Residual variance:
σ2 0.516 (0.075)
Variance components of bi:
d11 0.063 (0.031)
d12 −0.023 (0.053)
d22 0.435 (0.202)
Variance inflation parameter:
λ 0.515 (0.132)
−2 log-likelihood 333.3
10, 50, 100, 200, 500, 1000 and with 10 repeated measure-
ments per subject, we generated 1000 data sets from
the one-compartment model (5) with the pharmacoki-
netic parameters given in (7). In simulations, the fixed-
effect parameters were fixed at β1 = −3.2, β2 = 0.5,
β3 = −2.4, in accordance with the estimates in Ta-
ble 2. Also, we set λ = 0.5 and σ2 = 0.5. For sim-
plicity in the simulations, we here assumed that the
two random effects bi1 and bi2 are independent (in Ta-
ble 2 the estimate of Cov(bi1, bi2) is very close to 0).
Note that this assumption may not be realistic in prac-
tice and we would not make this assumption in our
analysis of the theophylline data. We generated each of
the random effects bi1 and bi2 from four distinct distri-
butions: N(0, 1), Chi-squared(2), Log-normal(3, 1), and
F(1, 7). All the generated random effects were shifted
and rescaled such that bi1 and bi2 have both zero mean,
but with different variances equal to 0.1 and 0.5 respec-
tively, in accordance with the estimates of their vari-
ances in Table 2.
For each simulation setting, we first fitted the one-
compartment model (5)-(7) to each of the generated
data sets under a bivariate normality assumption of bi1
and bi2, and then for each fitted model we carried out
both the asymptotic and bootstrap tests using the al-
gorithms on page 4. We computed the rejection rates
of the asymptotic and bootstrap tests. When the true
random-effects distribution was normal, the rejection
rate would actually correspond to the Type I error rate,
otherwise it represents the power of the test to detect
misspecification.
The rejection rates (powers) of the asymptotic test
and the bootstrap test are shown in Figure 2 with solid
and dashed lines, respectively. Figure 2(a) indicates that
the asymptotic test shows a Type I error rate smaller
than the nominal level 0.05 while it gets closer to the
nominal level when N increases. Thus, the asymptotic
test is conservative in terms of Type I error when the
sample size is not very large. The results in Figure 2(b,c,d)
show that the power of the asymptotic test is not high
when the sample size N is small, but it increases with
the sample size. On the other hand, the results suggest
that the bootstrap test has the correct Type I error
rate with a high power and it is more powerful than the
asymptotic test when the sample size N is small. Based
on the simulation results, we conclude that a sample
size of at least 200 is required to apply the asymptotic
test to the one-compartment model (5)-(7) fitted to the
theophylline data. Therefore, we should use the boot-
strap test for the theophylline data.
In the above simulations, we used ni = 10 because
the theophylline data contain 10 repeated measurements
for each subject. However, in many other applications
there might be a smaller number of repeated measure-
ments per subject (i.e., sparse sampling). To examine
the performance of the proposed diagnostic test in such
situations, we repeated the previous simulation study
but with ni = 5. The simulation results, presented in
Figure 3, suggest that both the asymptotic and boot-
strap tests lose power when the number of repeated
measurements per subject gets smaller. However, the
power loss from 10 repeated measurements to 5 re-
peated measurements is not substantial especially when
the number of subjects N is large.
We also ran simulations to see how the diagnostic
test performs when the estimates of random effects are
shrunk. For this, a good example is when random ef-
fects are generated from a mixture of normals, then
the estimates of random effects obtained under the uni-
modal normality assumption are potentially shrunk to-
ward the mean (see [21] and [23]). We repeated the
previous simulation study but with random effects bi1
and bi2 each generated from
1
2N(−2, 1)+ 12N(2, 1). The
simulation results for ni = 10 and ni = 5, presented in
Figure 4, show that the asymptotic and bootstrap tests
perform reasonably well for the case when estimates
of random effects are shrunk. It is probably because
the proposed diagnostic method does not use the esti-
mates of random effects, and instead it is based on the
marginal likelihood after integrating out the random
effects. Note that only the estimates of fixed-effects pa-
rameters and residual variance are used in our method
just for calculation of the estimated gradient function.
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(a) (b)
(c) (d)
Fig. 2 Rejection rates (powers) of the asymptotic test (solid line) and the bootstrap test (dashed line) at the significance
level 0.05 with ni = 10 repeated measurements per subject and under four random-effects distributions: (a) N(0, 1), (b)
Chi-squared(2), (c) Log-normal(3, 1), and (d) F(1, 7). Note that all the generated values of random effects were shifted and
rescaled such that random effects bi1 and bi2 have both zero mean and variances equal to 0.1 and 0.5, respectively.
Analysis of the theophylline data
In our initial analysis of the theophylline data above,
we found that the one-compartment model (5) with
the pharmacokinetic parameters given in (7) produces
a better fit than with the pharmacokinetic parameters
in (6). There it was assumed that the random effects
are normally distributed. Now, we want to check if the
normality assumption is valid. For this purpose, we first
look at the gradient function plot obtained from fitting
the one-compartment model (5) with the pharmacoki-
netic parameters (7) to the theophylline data. The gra-
dient plot, presented in Figure 5, shows some fluctua-
tions from 1 and one may conclude that the bivariate
normal distribution is not a proper choice. However,
these fluctuations may be due to random variability
in the estimates of parameters needed for calculation
of the gradient function. Thus, we shall apply the di-
agnostic test based on (4) to formally check if a bi-
variate normal distribution is appropriate for bi1 and
bi2. According to the simulation results, we should ap-
ply the bootstrap test as there are 12 subjects in this
dataset. The bootstrap test with 200 bootstrap samples
and with 1000 Monte Carlo integration nodes provides a
test statistic of 3.82, giving a p-value of 0.14. Therefore,
it suggests that a bivariate normal distribution is ap-
propriate for the random effects bi1 and bi2. Although
for the theophylline data the diagnostic test suggests
no evidence for misspecification of the random-effects
distribution, one might be cautious as the simulations
showed that the diagnostic test does not have a high
power to detect misspecification when the sample size
is very small.
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(a) (b)
(c) (d)
Fig. 3 Rejection rates (powers) of the asymptotic test (solid line) and the bootstrap test (dashed line) at the significance
level 0.05 with ni = 5 repeated measurements per subject and under four random-effects distributions: (a) N(0, 1), (b) Chi-
squared(2), (c) Log-normal(3, 1), and (d) F(1, 7). Note that all the generated values of random effects were shifted and rescaled
such that random effects bi1 and bi2 have both zero mean and variances equal to 0.1 and 0.5, respectively.
(a) (b)
Fig. 4 Rejection rates (powers) of the asymptotic test (solid line) and the bootstrap test (dashed line) at the significance
level 0.05 when random effects are generated from 1
2
N(−2, 1) + 1
2
N(2, 1), and with (a) ni = 10 repeated measurements per
subject and (b) ni = 5 repeated measurements per subject. Note that all the generated values of random effects were shifted
and rescaled such that random effects bi1 and bi2 have both zero mean and variances equal to 0.1 and 0.5, respectively.
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Fig. 5 Bivariate gradient function for the one-compartment
model (5)-(7) fitted to the theophylline data under a bivariate
normality assumption for bi1 and bi2.
Discussion
In this paper we have shown, via simulations and real
data, that our diagnostic test based on the gradient
function performs reasonably well in detecting misspec-
ification of the random-effects distribution in nonlinear
mixed-effects models. As expected, the asymptotic test
does not show a high power when the sample size is
small or moderate, while the bootstrap test performs
better for small samples. Since the bootstrap test is
time consuming when the sample size is very large, we
suggest the asymptotic test for sufficiently large sample
sizes, and the bootstrap test for smaller samples.
We have found that the power of our diagnostic test
also depends on the number of repeated measurements
per subject as well as the magnitude of variance compo-
nents. In our real data example, the estimates of vari-
ance components of bi1 and bi2 were very small and con-
sequently our simulation study conducted with those
small variance components did not show high power
values especially in small samples, while another simu-
lation study (not reported in the paper) with the same
settings but with larger variance components showed
that the power of our diagnostic test increases consid-
erably when the variance components are larger. There-
fore, one must be cautious when applying the proposed
diagnostic test to real data applications for which the
estimates of variance components are very small, unless
the sample size is very large.
When multiple random effects are present in the
model, the gradient function plot is not much helpful
because it needs evaluating a three or higher dimen-
sional plot of gradient function which may not be easy
to interpret and judge. Therefore, it is recommended to
apply the formal diagnostic test based on the gradient
function when the model includes two or more random
effects.
We previously developed a bootstrap test based on
the gradient function (see [9]), however as shown in [8],
that bootstrap test does not have a good power even for
generalized linear mixed models, because it evaluates
the gradient function for a grid of random effects only
and moreover its bootstrap algorithm was developed
under the normality of maximum likelihood estimates
which is a large sample property. Instead, our bootstrap
test in this paper uses a powerful test statistic as well
as a simple bootstrap algorithm.
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